Modality
Fusion Protein
MOA
CDK2i
Target
IL-17A
Pathway
Lipid Met
CML
Development Pipeline
Preclinical
~Jan 2018
→ ~Apr 2019
Phase 1
~Jul 2019
→ ~Oct 2020
Phase 2
~Jan 2021
→ ~Apr 2022
Phase 3
~Jul 2022
→ ~Oct 2023
NDA/BLA
Jan 2024
→ Jun 2029
NDA/BLACurrent
NCT07310733
1,829 pts·CML
2024-01→2029-06·Terminated
1,829 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-06-203.2y awayPh3 Readout· CML
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2029-06-20 · 3.2y away
CML
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07310733 | NDA/BLA | CML | Terminated | 1829 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| REG-2328 | Regeneron | Phase 1 | BCMA |